SCHEMBL7765313

SCHEMBL7765313

CN1C(=O)N(Cl)C(C)(C)C1=O

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL123299 0.79 POLB (0.30) POLB
SCHEMBL1578764 0.78 LMNA (0.32) LMNA
SCHEMBL5855092 0.77 POLB (0.35) LMNAPOLB
SCHEMBL417571 0.76 PLA2G7 (0.39) LMNAPOLB
SCHEMBL22578 0.75
Hypochlorous Acid SCHEMBL6047066 0.75
SCHEMBL10874274 0.74
SCHEMBL6047067 0.73
SCHEMBL1320959 0.73 POLB (0.45) POLB
SCHEMBL7764140 0.72 LMNA (0.34) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4212937-A NITROGEN-CONTAINING HETEROCYCLIC BASE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1980-07-15 US claimed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 US disclosed
WO-2022161416-A1 AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 武汉朗来科技发展有限公司 2022-08-04 WO disclosed
US-20170273307-A1 SILANE-BASED ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THE SAME UNIV TRENT (CA) 2017-09-28 US disclosed
EP-0759189-B1 PHOTOTHERMOGRAPHIC ELEMENT WITH PRE-FORMED IRIDIUM-DOPED SILVER HALIDE GRAINS EASTMAN KODAK CO (US) 2001-05-30 EP disclosed
EP-0746799-B1 PHOTOTHERMOGRAPHIC ELEMENT WITH CORE-SHELL-TYPE SILVER HALIDE GRAINS IMATION CORP A DELAWARE CORP (US) 1998-07-15 EP disclosed
EP-0759189-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH PRE-FORMED IRIDIUM-DOPED SILVER HALIDE GRAINS Imation Corp. (US) 1997-02-26 EP disclosed
EP-0746799-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH CORE-SHELL-TYPE SILVER HALIDE GRAINS Imation Corp (a Delaware Corporation) (US) 1996-12-11 EP disclosed
US-5563030-A HIGH DENSITY, RESOLUTION, SHARPNESS, SHELF LIFE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-10-08 US disclosed
WO-1995030931-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH PRE-FORMED IRIDIUM-DOPED SILVER HALIDE GRAINS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-11-16 WO disclosed
WO-1995022785-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH CORE-SHELL-TYPE SILVER HALIDE GRAINS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-08-24 WO disclosed
US-5434043-A Photothermographic element with pre-formed iridium-doped silver halide grains MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-07-18 US disclosed
US-5382504-A Negative photographic element MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-01-17 US disclosed
US-4347310-A INCREASED PHOTOSENZITIVITY USING GUANIDINE DERIVTIVES AS SENSITIZERS; PHOTOSTABILITY; STORAGE STABILITY ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1982-08-31 US disclosed
US-4212937-A NITROGEN-CONTAINING HETEROCYCLIC BASE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170273307-A1 SILANE-BASED ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THE SAME CUTA, SMURF1, TET1 LMNA 2746/4885POLB 3134/4885
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors ENPP1, ENPP3, PDE4A LMNA 1314/4885POLB 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.